FDA
-
-
-
-
-
-
-
SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment
-
-
-
-
-
-
-
SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination
-
-
-
-
-
-
-
SciSparc (SPRC) Announces Successful Final Phase IIa Results, Meeting End Points of its Phase IIa Alzheimer Disease Patients with Agitation Trial
-
-
-
-
-
-
-
SciSparc Successfully Completed Production of its Proprietary Drug Candidate SCI-110 for its Upcoming Clinical Trial On Tourette Syndrome
-
-
-
-
-
-
-
SciSparc Signs Clinical Trial Agreement with Yale University to Conduct its Phase IIb Trial in Tourette Syndrome
-
-
-
-
-
-
-
Prof. Avi Schroeder Joins SciSparc's Scientific Advisory Board to Support the Company's Development of SCI-160 for Treating Pain
-
-
-
330,185 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

